Losing To No Decision: A Diagnostic And A Fix

Gartner research shows roughly half of B2B opportunities end in no decision. The pattern is predictable and largely fixable. Here is the diagnostic and the operational fix.
Shankar Ganapathy
Co-Founder, Boomerang
Apr 24, 2026

The most common loss reason in enterprise B2B sales is not "we lost to a competitor." It is "no decision." Gartner research has consistently shown roughly half of qualified B2B opportunities end this way. The buyer ran an evaluation, considered the options, and chose to do nothing.

For the rep, "no decision" is the most frustrating loss reason because there is no clear lesson. You did not lose on price. You did not lose on product. You lost because the buyer decided the change was not worth making this quarter.

The good news: most no-decision losses share a structural pattern, and the pattern is fixable. This post is the diagnostic and the operational fix.

Why deals die at no decision

Three structural reasons, in order of frequency.

One. No real mobilizer. The buying group had a champion who advocated for your specific solution, but no one whose role was to build internal consensus around making a decision at all. The committee evaluated, did not converge, and the path of least resistance was to defer. See The Mobilizer Playbook.

Two. Unidentified blocker. Someone with veto power, often not on the formal buying committee, quietly killed the deal in a 15-minute internal conversation. The rep never engaged with the blocker because they did not know the blocker existed. See The Hidden Blocker That Kills Your Deal.

Three. The deal was structurally too small to break inertia. For some buyers, even a well-validated, well-championed deal does not produce enough urgency to override the cost of changing. The default to keep the existing solution is almost always cheaper in the short term than buying a new one. Without acute urgency, no-decision wins by inertia.

The diagnostic

For any deal that is at risk of no-decision (typically detectable 6 to 8 weeks before the close date), three questions to ask the champion.

Question 1. Who in your company is going to push this decision forward beyond evaluation? This is the mobilizer-detection question. The honest answer reveals whether anyone on the buying side has internal motivation to actually make a call.

Question 2. Is anyone in the buying group quietly leaning toward "let's wait"? This is the blocker-detection question. Real champions know who is hesitating internally. The conversation surfaces the political resistance.

Question 3. What happens at your company if you do not make this decision this quarter? This is the urgency-detection question. If the answer is "nothing meaningful changes," the deal is structurally vulnerable to no-decision. If the answer is "we have a specific consequence we are trying to avoid," there is real urgency.

The combination of answers tells you the deal's structural risk. A deal with no clear mobilizer, a suspected blocker, and weak urgency is heading to no-decision regardless of what your AE does in the next 6 weeks.

The operational fix

Three moves, depending on the diagnostic.

If no mobilizer is identified. The rep's next priority is to find or build one. This usually means expanding the buying committee to include someone with the right mobilizer profile. See The Mobilizer Playbook for the identification and activation playbook. Without a mobilizer, the deal will not close this cycle. Forecast accordingly.

If a blocker is detected. Engage them directly. The right path depends on whether the blocker is convertible (substantive concerns that can be addressed) or structural (preference for the alternative, personal relationship with the incumbent). Either way, the rep needs to know what the blocker thinks before procurement, not after. See The Hidden Blocker for the detection and engagement options.

If urgency is weak. This is the hardest to fix because it is genuinely about the buyer's situation, not about your sales process. Two options. First, work with the champion and mobilizer to amplify the urgency case. "What would have to change inside your company to make this a Q3 priority instead of Q4." Sometimes there are unspoken pressures that can be surfaced. Second, accept that this cycle is not the close cycle, build the relationship for renewal in 12 to 18 months, and redirect resources.

The mistake is to push hard on a deal with structurally weak urgency. The buyer will resist. The rep will burn cycles. The deal will still go to no-decision, and now the relationship is damaged for the next cycle.

What the data says

Customer outcomes I have visibility into suggest:

Deals that pass the three-question diagnostic (clear mobilizer, no blocker, real urgency) close at 50 to 70 percent. Run them as primary forecast deals.

Deals that fail one of the three questions close at 25 to 35 percent. Run them with the operational fix; do not commit to them in your forecast.

Deals that fail two of the three close at 5 to 15 percent. Move them to "build relational coverage" stage; do not run them as forecast deals this cycle.

Most teams over-forecast because they include deals in the second and third categories in their commit number. The result is a chronic 20 to 30 percent forecast miss that the team is mystified by. The diagnostic surfaces the structural causes.

From the trenches

The frameworks (MEDDPIC, BANT, CHAMP) all add value, but the single biggest determinant of "no decision" I have seen across hundreds of deals is the absence of an equipped champion. If you have a champion, they almost always find a way to surface the metric, the economic buyer, the procurement path. If you do not have one, no framework saves the deal.

What does it mean to have a champion? Picking the right account is step zero to step one — the signals work (funding events, headcount expansion, leadership change, regulatory pressure). But signals only tell you the account is in motion. Once you pick the account, the next move is finding the person most likely to solve the problem you address, where that problem is a CEO or board priority. That person becomes a candidate champion.

The candidate champion is busy. They are trying to accomplish outcomes. They are also being pitch-slapped daily. So finding an introduction that delivers credibility is the operational unlock. Depending on the size of the deal, the right credibility-carrier is different — a customer vouches at the AE level, a partner vouches at the VP level, a board member or investor vouches at the CRO or CEO level. And the champion has to feel that you personally, and the business you represent, can help them drive their outcome.

Once a champion is willing to put their hand on the table for you, the no-decision risk drops dramatically. I have watched this pattern across deals at HP, AWS, Informatica, Blackbaud, and across our current customer base at Boomerang. The pattern repeats because the underlying dynamic does.

What to do this quarter

Pull every deal in your active pipeline that is forecast to close in the next 90 days. Run the three-question diagnostic on each. Honest answers, not optimistic ones.

For deals that fail the diagnostic, choose the right operational fix or move them to the appropriate stage. Update the forecast based on the corrected probability.

Build the diagnostic into your stage-promotion process. A deal should not advance to "commit" stage without passing all three questions.

For the related deal-mechanics work, see How To Find The Real Economic Buyer, Champion Validation: A 5-Question Test, The Hidden Blocker That Kills Your Deal, and The Mobilizer Playbook. Together these four diagnostics produce the picture of whether the deal is structurally ready to close.

For the broader architecture, see our buying group intelligence and path to power pillars.

No-decision is not random. It is the predictable outcome of structural conditions that can be detected weeks before the close date. The teams that detect them early either fix the conditions or stop forecasting the deal. The teams that do not detect them keep including doomed deals in their commit number and missing quota. The diagnostic is the small operational discipline that separates the two.


Shankar Ganapathy is the co-founder of Boomerang, the operational layer for relationship-led pipeline. Before founding Boomerang, he led product in the account planning signals space.